Israel Englander’s Tonix Pharmaceuticals TNXP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.3M | Buy |
966,932
+747,259
| +340% | +$9.64M | ﹤0.01% | 2075 |
|
|
2026
Q1 | $3.02M | Buy |
219,673
+196,727
| +857% | +$3.03M | ﹤0.01% | 3454 |
|
|
2025
Q4 | $358K | Sell |
22,946
-29,785
| -56% | -$549K | ﹤0.01% | 5150 |
|
|
2025
Q3 | $1.27M | Buy |
52,731
+43,854
| +494% | +$1.63M | ﹤0.01% | 4427 |
|
|
2025
Q2 | $319K | Sell |
8,877
-27,984
| -76% | -$733K | ﹤0.01% | 5164 |
|
|
2025
Q1 | $659K | Buy |
36,861
+34,020
| +1,197% | +$690K | ﹤0.01% | 4642 |
|
|
2024
Q4 | $93.7K | Sell |
2,841
-773
| -21% | -$16.1K | ﹤0.01% | 5486 |
|
|
2024
Q3 | $53.7K | Buy |
+3,614
| New | +$145K | ﹤0.01% | 5680 |
|
|
2024
Q2 | – | Sell |
-36
| Closed | -$21.2K | – | 6539 |
|
|
2024
Q1 | $21.2K | Buy |
36
+28
| +350% | +$30.2K | ﹤0.01% | 5813 |
|
|
2023
Q4 | $10.9K | Buy |
8
+2
| +33% | +$3.22K | ﹤0.01% | 5726 |
|
|
2023
Q3 | $10.2K | Buy |
+6
| New | +$21.9K | ﹤0.01% | 5759 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$5K | – | 6866 |
|
|
2022
Q4 | $5K | Sell |
1
-19
| -95% | -$164K | ﹤0.01% | 6299 |
|
|
2022
Q3 | $217K | Buy |
20
+13
| +186% | +$319K | ﹤0.01% | 5607 |
|
|
2022
Q2 | $222K | Buy |
+7
| New | +$517K | ﹤0.01% | 5579 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 6768 |
|
|
2021
Q4 | – | Hold |
0
| – | -$137K | – | 7380 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | -$487K | – | 6288 |
|
|
2021
Q2 | $922K | Sell |
1
-1
| -50% | -$735K | ﹤0.01% | 4739 |
|
|
2021
Q1 | $1.26M | Buy |
+2
| New | +$1.53M | ﹤0.01% | 3996 |
|
|
2020
Q4 | – | Hold |
0
| – | -$68 | – | 5592 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 4275 |
|
|
2018
Q3 | – | Hold |
0
| – | -$62K | – | 4277 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 3690 |
|
|
2017
Q3 | – | Hold |
0
| – | -$80K | – | 3859 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 3325 |
|
|
2016
Q4 | – | Hold |
0
| – | -$76K | – | 3737 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3157 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 2046 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 1824 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 1130 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 1446 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 1312 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 3109 |
|
Other funds holding TNXP
JHC
II
Israel Englander's TNXP Position: Q2 2026 in Review
Israel Englander increased its Tonix Pharmaceuticals (TNXP) stake by 340% in Q2 2026, buying an estimated $9.64M and bringing the position to 966,932 shares worth $12.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2075.
Israel Englander first reported a position in TNXP in Q1 2021 and has held it in 16 quarters since. 102 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.
- Israel Englander held 966,932 shares of Tonix Pharmaceuticals worth $12.3M as of Q2 2026.
- Israel Englander bought 747,259 Tonix Pharmaceuticals shares in Q2 2026, an estimated $9.64M.
- Tonix Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2075 holding.
- Israel Englander first reported a position in Tonix Pharmaceuticals in Q1 2021 and has held it in 16 quarters since.
- 102 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.